ZURICH, June 25 (Reuters) - Shares in Swiss biotech company Basilea fell by as much as 11.5 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.
The company said in a statement on Wednesday it had been told by the U.S. Food and Drug Administration (FDA) that potential regulatory approval of ceftobiprole, a broad-spectrum intravenous antibiotic, to treat pneumonia would require additional phase 3 data.
20:52 After earning crush, Tesla expected to unveil 'solar roof', integrated home battery36
12:23 Lockheed Martin's quarterly profit handily beats estimates24
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents19
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion14